Evidence for the existence in human plasma of a protein with high affinity for the binding of corticosteroids, which we have named transcortin, has been recently published from several laboratories (1) (2) (3) (4) (5) . Even though the concentration of transcortin is considerably lower than that of albumin, the former binds cortisol approximately 6,000 times as strongly as does the latter (5) . Therefore, under physiological conditions most of the plasma cortisol has been shown to be bound to transcortin. Transcortin appears to be saturated at plasma levels of cortisol of approximately 30 to 40 ug. per cent (4) (5) . Some of the characteristics of the corticosteroid-binding protein have been described by Daughaday (2, 6), Bush (3), Upton and Bondy (4) and ourselves (5) .
In a previous paper we reported a method for measuring the binding capacity of transcortin in plasma and showed it to be increased in the plasma of pregnant women (5) . Since the concentration of transcortin may play an important role in the metabolism and biological effects of cortisol, it appeared worthwhile to ascertain the transcortin capacity in several clinical states. Data are presented in this paper on the transcortin binding capacity in the plasma of newborn infants and their mothers; in normal children of various ages; in patients with cirrhosis of the liver; in patients with miscellaneous diseases; and following the administration of estrogenic substances.
METHODS AND MATERIALS
Maternal and fetal blood was taken into heparinized syringes immediately following delivery from the antecubital vein and the umbilical vein of the placenta, respectively. The plasma was separated from the erythro-*This investigation has been supported in part by a grant (A-1240) from the National Institute of Arthritis and Metabolic Diseases of the National Institutes of Health, United States Public Health Service.
cytes shortly following withdrawal of the blood. Some of the plasma was stored at -100 C. The determination of the binding capacity of transcortin was performed and calculated according to methods previously described (1, 5) . Unless otherwise indicated, all binding experiments were performed by dialyzing 10 ml. of diluted plasma (1: 5 with physiological saline) against 30 ml.
of saline containing approximately 0.3 ,tg. of C14-cortisol.
The binding was determined with and without the addition of 1 ,ug. of cortisol to the saline in order to measure the decrease in the binding caused by the addition of the carrier cortisol. In a previously published paper (5) we demonstrated that under the conditions of our assay the binding of cortisol by plasma was essentially due to transcortin and not to other plasma proteins. Hence, the term "transcortin binding of C14-cortisol" will refer to the percentage of C14-cortisol bound by 10 ml. of diluted plasma, and the term "transcortin capacity" will be used to indicate the decrease in binding caused by the addition of 1 ,ug. of cortisol in the dialysis conditions outlined above. It should be pointed out that the "binding capacity" will be inversely related to the decrease in the binding caused by the addition of 1 ,g. of cortisol, i.e., the less the decrease in the binding, the higher the binding capacity, and vice versa.
Some of the shortcomings of the method used were discussed previously, but it would appear that this offers, at present, the best approach to the measurement of transcortin capacity (5) . The major shortcoming of the method is the inability to measure the actual concentration of transcortin in the plasma. Nevertheless, knowing three values (the initial binding of C14-cortisol, the binding capacity, and the endogenous cortisol concentration), one can locate reliably the point on one of the binding curves ( Figure 1 ) at which a particular experiment was performed. Since the determination of endogenous cortisol concentrations is impractical, we have relied on 17-hydroxycorticosteroid concentrations (17-OHCS) as approximations of cortisol levels, taking the values either from the literature or from our own data. The radioactivity in the samples and the plasma 17-OHCS were determined by methods previously described (7, 8) . The electrophoretic pattern of the plasma proteins was determined in a Perkin-Elmer Model 38 electrophoresis apparatus. All samples were dialyzed to equilibrium in phosphate buffer, pH 8.6 (0.1 M), and the electrophoretic determinations were made according to standard techniques.
RESULTS
The plasma of 10 normal adult males and females ( years. In many cases it was necessary to pool the plasmas of several children. No significant difference was observed in the transcortin binding of C14-cortisol and capacity among the various age groups studied (Table II) . Unfortunately, we do not have data on transcortin levels in the age group of 12 to 18 years.
Effects of estrogen administration on the binding capacity
In previously published work we demonstrated increased transcortin binding of C14-cortisol and capacity during pregnancy, especially the last trimester (5) . To ascertain whether these increased transcortin levels might in some measure be due to the increased circulating levels of estrogens, several subjects were given stilbestrol or ethinyl estradiol and the plasma transcortin levels and the 17-OHCS were measured. The data are shown in Table II (40 year female), and the ages ranged from 32 to 60 years. In general, the transcortin binding of C14-cortisol and capacity were not significantly different (0.3 < p < 0.4) from those observed in normal subjects. There appeared to be no correlation between the transcortin levels and the clinical or laboratory findings. In Table V are shown the data obtained in six patients with multiple myeloma. As a group, the transcortin binding of C14-cortisol and capacity of the plasma of these subjects did not differ materially from those seen in normal subjects. There was no apparent correlation between the plasma protein changes and the transcortin levels. In Table VI arthritis by transcortin, since these conjugates might encroach on the ability of transcortin to bind cortisol. Following the injection of C14-cortisol into a normal male subject, the urine obtained during the initial two hours following the administration of the C14-cortisol was used as a source of conjugated metabolites of C14-cortisol. One ml. of the urine, containing approximately 10,000 cpm, was added either to 5 per cent human serum albumin (HSA) or to saline and dialyzed against undiluted plasma. Dialysis was performed for eight days, since preliminary observations indicated that equilibrium was not established between the plasma and the HSA when dialyzed for three days, but did occur in eight days. The binding of urinary C14-cortisol metabolites by the plasma was 1 per cent when the plasma was dialyzed against albumin. It appears, therefore, that there is no special protein which binds the conjugated metabolites of cortisol, comparable to that which binds cortisol. The binding exhibited by the plasma (54 to 59 per cent) dialyzed against the urinary metabolites of cortisol was similar to that found with HSA (9). Since the amount of cortisol and other steroid metabolites present in the urine sample added to the dialysis system was calculated to be at least 10 ,ug., and since this amount of steroid metabolites may exceed the binding capacity of the plasma transcortin in the 10 ml. of plasma, the following experiments were performed. Dialysis of diluted (1: 5) plasma was performed against saline to which 0.3 Mg. of C14-cortisol was added. In addition, in another series, 1 ml. of urine from a normal male subject was added to the saline in order to establish the competition of the nonradioactive steroid metabolites of cortisol (and other steroids) with the C14-cortisol for transcortin. In a third experiment some of the urine was extracted with ether, boiled, cooled, then added to the saline, in order to exclude any unconjugated metabolites. Again, the urines used were calculated to contain a minimum of 10 Mg. of cortisol metabolites. When no urine was present, 94 per cent of the C14-cortisol was bound by the plasma; when etherextracted urine was added 84 per cent was bound; and with an original urine 80 per cent was bound. The findings indicate that large amounts of conjugated metabolites of cortisol (and of other steroids) in the urine, and, by inference, in plasma, do not compete significantly with the binding of cortisol by transcortin.
DISCUSSION
For a fuller interpretation and understanding of the results presented it may be worthwhile to consider some of the aspects of the binding of a ligand (cortisol) by a protein (transcortin). As shown in Figure 1 In previously published work it was shown that the transcortin binding of C14-cortisol and capacity are increased during pregnancy, especially in the last trimester (5), findings compatible with increased plasma transcortin levels (see Figure 1) . Since there is a definite increase in the plasma cortisol during that period of pregnancy, without classical signs of hypercorticism, we advanced the hypothesis that transcortin-bound cortisol was biologically inactive and that the concentration of cortisol in the plasma would have to exceed the effective capacity of transcortin before physiological, and especially pharmacological, effects of cortisol became evident. In the present study the transcortin binding of C14-cortisol in the plasma of the mothers immediately post partum was 88 per cent on the average as compared to 96 per cent obtained during the last trimester. This difference is best explained by the substantial rises in the cortisol levels in women in labor (10, 11) with resultant encroachment on the capacity to bind the added C14-cortisol (see Curve B in Figure 1 ). Nevertheless, the binding capacity, as shown by the decrease induced by the addition of 1 ,ug. of cortisol, remained high, especially when compared to that of normal subjects.
From the foregoing discussion it appears that patients with increased levels of plasma transcortin should metabolize C14-cortisol slower than normal subjects. Decreased rates of metabolism of C14-cortisol have been shown to occur in pregnant women (12, 13) . It should be emphasized, however, that transcortin may be only one of the factors influencing rates of cortisol metabolism and that the other factors (state of liver function, metabolic rate and so forth) probably play important roles. This is illustrated by the transcortin binding of C14-cortisol and capacity in newborn infants. Even though the plasma 17-OHCS are much lower in the plasma of the newborns (cord blood) immediately post partum than in the plasma of the mothers (10, 11, 14) , but on the average similar to those of normal adults, the transcortin binding of C14-cortisol was the lowest observed by us thus far (see Curve C in Figure 1 ). Since it has been shown that the plasma 17-OHCS decrease to extremely low levels in newborn infants within 24 hours following birth (14) , it will be interesting to ascertain the transcortin levels during the first few weeks of life. Upon the addition of 1 ug. of cortisol the binding decreased to very low levels in the newborn infants (mean, 47 per cent, compared to 78 per cent in the mothers, 58 per cent in normal subjects and 83 per cent in the third trimester of pregnancy). Since it has been shown that the concentration of albumin in the plasma of newborn infants is equal to that present in the plasma of children or adults (15) , the binding of C14-cortisol exhibited by the plasma of newborn infants, following the addition of 1 ,ug. of cortisol, can be ascribed to its content of albumin (1) . In spite of lower transcortin binding of C14-cortisol, newborn infants have been shown to metabolize cortisol at a slower rate than older children (16, 17) . It is possible that the liver is implicated in the slower metabolism of cortisol in the newborn infant.
The transcortin binding of C14-cortisol in children, exclusive of the newborn infants, was somewhat higher than in adult subjects. It is possible that the increased binding shown by the older children's plasma may be due to slightly lower circulating levels of cortisol as inferred from the plasma 17-OHCS concentration (18) and may also explain the normal (23 per cent) drop in the binding upon the addition of 1 ,ug. of cortisol. Again, for a fuller understanding of the last statement it may be worthwhile to refer to Curve A in Figure 1 . It is apparent that the binding of the C14-cortisol by transcortin will be greatly dependent on the concentration of endogenous cortisol in the plasma. At high concentrations of cortisol the binding will be lower down on the curve and the reverse is true for low cortisol levels. Whether the cortisol levels are high or low, but still within the normal range, the binding capacity will be of approximately the same order of magnitude since the initial point of the binding in both cases will be usually located on the upper half of the sloping curve.
Of great interest was the increased transcortin binding of C'4-cortisol capacity brought about by the administration of estrogens. We interpret our data to indicate that the drug caused a sharp increase in the concentration of transcortin. This probably explains, in large measure, the ability of subjects given estrogens to tolerate very high levels of cortisol (13, 19) . It will be interesting to establish which occurs first, the rise in plasma transcortin or the 17-OHCS concentration. Since it has been shown that the total amounts of corticosteroids produced and excreted in the urine by patients receiving estrogens and in pregnant women are normal or reduced (13, 20, 21) , con-comitant with high plasma 17-OHCS, it can be predicted that the effect of the estrogens or pregnancy is to increase the plasma transcortin levels before the 17-OHCS rise. The increased amounts of transcortin would bind more cortisol and the 17-OHCS in the plasma would rise, due to the unavailability for metabolism of the transcortinbound steroid. The increased transcortin binding of C14-cortisol capacity in pregnancy may possibly be due to the increased levels of circulating estrogens. The binding capacity increased with time during the administration of the estrogens.
Since the possibility exists that the increased amounts of transcortin induced by estrogen administration originate in the liver, a group of patients with cirrhosis of the liver was examined for transcortin binding of C14-cortisol and capacity. Both were found essentially normal. Two explanations may be advanced for this finding. It is possible that a cirrhotic liver would synthesize lesser amounts of transcortin were it not for the stimulating effect of the increased circulating levels of the estrogens probably present in this condition. The other possible explanation merely states that the liver is not the site of transcortin synthesis. It was with this possibility in mind that several conditions associated with abnormal protein metabolism (multiple myeloma, rheumatoid arthritis, nephrosis) were investigated regarding the transcortin binding of C14-cortisol and capacity in the plasma of these patients. Even though some changes from the normal were seen in the patients, especially those with nephrosis and rheumatoid arthritis and in a few patients with multiple myeloma, in general, the transcortin levels were not greatly divergent from those of normal subjects. Daughaday (22) has published the corticosteroidbinding capacity of a relatively small number of patients and has shown it to be decreased in two patients with portal cirrhosis and in one with acute hepatic necrosis. One subject with nephrosis and another with multiple myeloma also had decreased binding capacity. Even though an occasional patient with the above diseases in our studies showed decreased transcortin binding of C14-cortisol and capacity, larger series of these patients will have to be examined before more definite conclusions can be reached regarding the transcortin levels.
Special attention must be devoted to nephrosis, since the a1-globulin levels tend to he low in patients with the syndrome and transcortin is thought to be an a,-globulin (2, 5) .
It would appear from the results presented that the various conjugated metabolites of cortisol and other steroids in the urine are not bound by transcortin to any significant extent. Hence, in all probability, the conjugated metabolites in the blood do not interfere with the binding of cortisol. SUMMARY 1. The plasma transcortin binding of C14-cortisol and capacity, when compared with those of normal adults, are low in newborn infants, possibly increased in children, normal in subjects with cirrhosis of the liver, probably reduced in subjects with the nephrotic syndrome and in some patients with multiple myeloma and slightly increased in subjects with rheumatoid arthritis.
2. The administration of estrogens causes greatly increased transcortin binding of C14-cortisol and capacity in the plasma concomitant with greatly increased levels of the 17-OHCS. Effects of hypercorticism are probably prevented in these subjects by the transcortin binding of cortisol, which is thought to render cortisol biologically inactive and not available for metabolism.
3. The conjugated metabolites of cortisol and other steroids were not bound significantly by transcortin.
